Sunday, August 01, 2021 12:14:44 AM
"In early 2011, Stephane Bancel was running the French diagnostics company BioMérieux, the executive offices of which were in Kendall Square, and was starting to think about what was next. At the time, BioMérieux was doing $2 billion in annual sales, and Bancel was being headhunted to run companies two and three times its size. Afeyan himself had tried to hire him to run a startup a couple of times, but Bancel had always turned him down. “I told him I was willing to take a career risk by working on something that might not work,” Bancel recalls about those early conversations with Afeyan. “But it would have to be something that, if it worked, would change the world.”
So in February 2011, when Afeyan called Bancel and asked him to stop by his office after work one evening, Bancel knew Afeyan had to have something interesting. It was about 6 p.m. by the time Bancel made it over to Flagship, where Afeyan delivered his pitch: He wanted Bancel to work on a startup that had so far hired only a single staff scientist, and had conducted just one mouse trial. Nevertheless, he told Bancel, the stakes were extremely high. If the technology proved successful in human beings, it would take Moderna weeks, not years, to make a new product. And there was more: Because the company would always be making the same thing—mRNA—the only thing that would ever have to change was the protein for which the mRNA would be coded. That meant that the company could make all of its products in the same plant—and that plant would cost a tenth of a typical one.
Afeyan also hit altruistic notes that he knew would appeal to Bancel. Because of its versatility and the small scale of its operations, Moderna would be able to go after the rare and tragic “orphan” diseases, those that most Big Pharma companies simply don’t pursue because there just aren’t enough patients in need of treatment to make the production of drugs for them financially worthwhile. Moderna, in other words, could save lives. Children’s lives.
Then Afeyan appealed to the capitalist in Bancel. Because Moderna would not be making drugs, he explained, but instead would be engineering the mRNA to code for those drugs, it could completely bypass all protections and compete immediately with patented drugs already on the market. And because the Moderna technology allows proteins to be made inside cells—something currently impossible with other protein-based therapeutics—it would be able to do everything current drugs do and many other things that they do not. Moreover, because the technology doesn’t touch DNA, it avoids the cancer risks traditionally associated with gene therapy. One other thought may have also occurred to Bancel as he listened to Afeyan: Given that Moderna’s technology isn’t a one-time fix, like gene therapy, patients would have to keep buying the company’s products.
Bancel left the meeting with his head spinning at the scientific and business potential of Moderna. In the weeks that followed, he interviewed the others involved with the company, and then took his wife out to dinner at Bin 26, near their Beacon Hill home. Over wine they talked through the offer. His wife asked him if he liked the science and the people he’d be working with. Bancel said he did. She asked if he could imagine a better way of using the next 10 years of his life. Bancel said he couldn’t—but worried out loud about the odds of failure. “She told me to stop being French,” he recalls, “and not to be afraid of taking a risk.” In the end, he decided to take the job. “I knew I’d never forgive myself,” he says, “if I’d turned down the chance to run the next Genentech.” The next day, he called Afeyan and told him he was in.
When Bancel broke the news of his departure to the board of directors at BioMérieux, he says, they reacted with complete confusion. Why on earth would he resign from such a powerful position to be employee number two at a startup with no products and only a single mouse experiment behind it? They tried to get him to stay, he says. But by then his mind was already elsewhere. The day I visited, I stood by as a Moderna scientist dropped the cells into the wells. We waited patiently for a short while, and then the wells turned a gratifying shade of blue. Moderna’s chief scientific officer, Tony de Fougerolles, patted the scientist on the back. “Congratulations,” he told him, “you just got another hit.” Then, turning to me, he added, “In five years, that mRNA you just saw there might treat a disease that is currently not druggable.”Bancel says Moderna has engineered more than 100 proteins this way. He won’t yet say which they are—but all, he assured me, are proteins the absence of which in a human body can cause disease. The company has been running experiments like this since the first few weeks of its existence.
Less
Recent MRNA News
- Shareholders that lost money on Moderna, Inc.(MRNA) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 09/26/2024 09:45:00 AM
- Moderna, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 8, 2024 to Discuss Your Rights - MRNA • PR Newswire (US) • 09/23/2024 09:45:00 AM
- The Gross Law Firm Reminds Moderna, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 8, 2024 - MRNA • PR Newswire (US) • 09/19/2024 09:45:00 AM
- The Gross Law Firm Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 09/16/2024 09:45:00 AM
- OpenAI Unveils Strawberry AI Model Series; Boeing Stock Falls 4% Amid Strike; HR Surges 20% on Growth Forecast • IH Market News • 09/13/2024 10:12:55 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 10:03:14 AM
- Moderna, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - MRNA • PR Newswire (US) • 09/12/2024 09:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 08:15:27 PM
- Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases • PR Newswire (US) • 09/10/2024 11:30:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/09/2024 07:29:35 PM
- Class Action Filed Against Moderna, Inc. (MRNA) - October 8, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 09/09/2024 02:26:00 PM
- Moderna, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before October 8, 2024 to Discuss Your Rights - MRNA • PR Newswire (US) • 09/05/2024 09:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 09:42:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 08:26:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 07:58:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 07:42:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 08:37:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 08:34:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 08:32:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/29/2024 08:45:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/29/2024 08:03:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 07:52:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 07:43:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 07:38:25 PM
- Class Action Filed Against Moderna, Inc. (MRNA) - October 8, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 08/29/2024 09:45:00 AM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM